Author

Linda Harndahl

Institution: Portsmouth Hospitals NHS Trust

Observed institution: Portsmouth Hospitals NHS Trust

ORCID: 0000-0002-5934-4399

Observed ORCID: 0000-0002-5934-4399

OpenAlex ID: A5031919705

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

2022 · Alasdair P S Munro, Shuo Feng, et al. · The Lancet Infectious Diseases · 175

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

2022 · Xinxue Liu, Alasdair P S Munro, et al. · Journal of Infection · 67

Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]

2023 · Xinxue Liu, Alasdair PS Munro, et al. · Journal of Infection · 1

Works count: 4

Citation count: 418

H-index: 3

I10-index: 3